Martin Belkin, DO, FACN, a neurologist at MIND and Medical Director of the MIND Multiple Sclerosis Center, served as an author on a newly published, multicenter international research study and as principal investigator for MIND. The study evaluated opicinumab, an investigational therapy for people living with relapsing multiple sclerosis (RMS).
As a participating clinical research site, MIND contributed patient participation and clinical oversight as part of a large, international research collaboration.
The study explored whether opicinumab could help support remyelination—the repair of myelin, the protective coating around nerve fibers in the brain and spinal cord—an approach aimed at restoring nerve function rather than focusing solely on reducing inflammation or relapses.
Although the trial did not demonstrate a statistically significant clinical benefit, the findings provide valuable insights that may inform the design of future remyelination research.
“I am honored to be included among this highly accomplished international group in this important publication. While the results were not what we had hoped for, the findings provide meaningful insights that will help guide future research in the pursuit of effective remyelination therapies for people living with multiple sclerosis.”
— Martin Belkin, DO, FACN
MIND participates in clinical research to advance scientific understanding and contribute to the development of future therapies, reinforcing its commitment to evidence-based neurological care. MIND’s MS Center is recognized by the National Multiple Sclerosis Society as a Center for Comprehensive MS Care.
Publication Credit:
Published in Multiple Sclerosis Journal (SAGE Publications)
Link to Abstract
© SAGE Publications































